Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

Decisions 26th June 2018

Checked: not set yet by Next Review: not set yet

At the meeting on the 26th June the following decisions were agreed:

 

New Drug Requests

 

Approved

Ketotifen eye drops

  • Approved for inclusion onto the formulary for seasonal allergic conjunctivitis as an alternative option to olopatadine or when a preservative free option is needed.

Aprokam® Cefuroxime injection

  • Approved for inclusion onto the formulary for prophylaxis of post-operative endophthalmitis during cataract surgery.

Lecicarbon A

  • Approved for inclusion onto the formulary for chronic constipation pending an adult constipation pathway

 

Shared Care Protocols

Sacubitril/valsartan (entresto)

  • Updated SCP agreed

Amantadine

  • Amended SCP presented for amantadine for the management of fatigue in patients diagnosed with multiple sclerosis. The group decided a separate SCP for amantadine for this indication was needed.  

Perampanel

  • Further information regarding contraception needed then SCP to be uploaded.

 

Other items

  • All new amber SCPs to be 3 months initially. 
  • Decision making tool for change of traffic light status discussed, to be amended and trialled at the next JFG.